دورية أكاديمية
أعرض في EDS

Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study.

التفاصيل البيبلوغرافية
العنوان: Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study.
المؤلفون: David E; Department of Dermatology, and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, New York, NY, 10029, USA., Shokrian N; Department of Dermatology, and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, New York, NY, 10029, USA.; Albert Einstein College of Medicine, New York, NY, USA., Del Duca E; Department of Dermatology, and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, New York, NY, 10029, USA., Meariman M; Department of Dermatology, and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, New York, NY, 10029, USA., Glickman J; Department of Dermatology, and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, New York, NY, 10029, USA., Ghalili S; Department of Dermatology, and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, New York, NY, 10029, USA., Jung S; Department of Dermatology, and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, New York, NY, 10029, USA.; School of Medicine, Vanderbilt University, Nashville, TN, USA., Tan K; Department of Dermatology, and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, New York, NY, 10029, USA., Ungar B; Department of Dermatology, and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, New York, NY, 10029, USA., Guttman-Yassky E; Department of Dermatology, and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, New York, NY, 10029, USA. emma.guttman@mountsinai.org.
المصدر: Archives of dermatological research [Arch Dermatol Res] 2024 Jul 23; Vol. 316 (7), pp. 487. Date of Electronic Publication: 2024 Jul 23.
نوع المنشور: Journal Article; Observational Study
اللغة: English
بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8000462 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-069X (Electronic) Linking ISSN: 03403696 NLM ISO Abbreviation: Arch Dermatol Res Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin : Springer Verlag
مواضيع طبية MeSH: Alopecia Areata*/drug therapy , Alopecia Areata*/immunology , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects , Antibodies, Monoclonal, Humanized*/administration & dosage , Hair*/growth & development , Hair*/drug effects, Humans ; Child ; Adolescent ; Female ; Male ; Retrospective Studies ; Child, Preschool ; Treatment Outcome ; Dermatitis, Atopic/drug therapy ; Dermatitis, Atopic/immunology ; Severity of Illness Index ; Immunoglobulin E/blood ; Immunoglobulin E/immunology ; Follow-Up Studies
مستخلص: Alopecia areata (AA) is nonscarring hair loss characterized by Th1 and concomitant Th2 skewing, particularly in atopic patients. Despite novel developments for adult AA, safe and effective treatments for pediatric patients remain limited. Dupilumab, with a well-studied safety profile, may have therapeutic potential for atopic pediatric AA. To evaluate the ability of dupilumab to regrow hair in pediatric AA patients. We conducted a single-center, retrospective, observational study to evaluate hair regrowth [using Severity of Alopecia Tool (SALT)] with dupilumab in 20 children with both AD and AA (age range 5-16 years, mean 10.8 years; baseline SALT range 3-100, mean 54.4). Patient demographics, atopic history, IgE and SALT scores were collected at 12wk follow-up visits, up to > 72wks, to evaluate hair regrowth. Spearman correlations with clinical data were performed. Patients showed clinical improvement over the follow-up period (range 24 to > 72wks, mean 67.6wks) with significant mean(± SD) reduction in SALT at 48wks versus baseline [20.4(± 35.1) vs 54.4(± 37.6), respectively; p < 0.01] and continued improvement up to > 72wks [2.2(± 4.9), p < 0.01]. Baseline SALT positively correlated with disease duration (r = 0.54, p < 0.01), and negatively correlated with improvement in SALT at weeks 24, 36, and 48 (|r|≥ 0.65, p < 0.01 for all comparisons). Baseline IgE positively correlated with improvement in SALT at week 36 (r > 0.60, p < 0.05). Dupilumab was well-tolerated, with no new safety concerns. These real-world data support the utility of dupilumab to safely treat pediatric AA patients, corroborating the role of Th2 skewing in children with AA and associated atopy, warranting larger clinical trials.
(© 2024. The Author(s).)
References: J Eur Acad Dermatol Venereol. 2021 Feb;35(2):464-475. (PMID: 32893393)
N Engl J Med. 2018 Jun 28;378(26):2486-2496. (PMID: 29782217)
J Am Acad Dermatol. 2021 Feb;84(2):370-380. (PMID: 32376430)
Ann Dermatol. 2013 Nov;25(4):471-4. (PMID: 24371395)
J Am Acad Dermatol. 2022 Jun;86(6):1318-1334. (PMID: 33940103)
J Allergy Clin Immunol Pract. 2020 Apr;8(4):1323-1328.e1. (PMID: 32036002)
JAAD Case Rep. 2021 Jul 27;16:82-85. (PMID: 34541272)
Ann Dermatol. 2014 Dec;26(6):722-6. (PMID: 25473224)
J Am Acad Dermatol. 2006 Sep;55(3):438-41. (PMID: 16908349)
Arch Dermatol Res. 2023 Dec;315(10):2877-2881. (PMID: 37682336)
Gene. 2013 Sep 25;527(2):565-9. (PMID: 23831512)
J Am Acad Dermatol. 2017 Nov;77(5):980-981. (PMID: 29029912)
J Eur Acad Dermatol Venereol. 2019 May;33(5):850-856. (PMID: 30762909)
J Eur Acad Dermatol Venereol. 2023 Mar 13;:. (PMID: 36914939)
Acta Dermatovenerol Croat. 2006;14(3):149-52. (PMID: 17010262)
Br J Dermatol. 2020 Oct;183(4):745-749. (PMID: 31749159)
Ann Dermatol. 2022 Aug;34(4):237-244. (PMID: 35948325)
J Dermatol. 2009 Jun;36(6):323-7. (PMID: 19500180)
Am J Clin Dermatol. 2022 May;23(3):365-383. (PMID: 35567671)
J Am Acad Dermatol. 2022 Aug;87(2):390-393. (PMID: 34915057)
J Am Acad Dermatol. 2016 Feb;74(2):372-4.e1-5. (PMID: 26775777)
JAMA Dermatol. 2013 Jul;149(7):789-94. (PMID: 23700152)
Dermatology. 2019;235(2):130-136. (PMID: 30566941)
JAMA Dermatol. 2019 Nov 1;155(11):1312-1315. (PMID: 31483439)
J Am Acad Dermatol. 2018 Nov;79(5):974-975. (PMID: 30318138)
J Am Acad Dermatol. 2020 Feb;82(2):407-411. (PMID: 31606479)
J Am Acad Dermatol. 2019 May;80(5):1389-1394. (PMID: 30633941)
Front Med (Lausanne). 2023 Oct 09;10:1253795. (PMID: 37877023)
Dermatitis. 2021 Oct 1;32(1S):S71-S80. (PMID: 34405829)
J Eur Acad Dermatol Venereol. 2023 Jan 6;:. (PMID: 36606560)
N Engl J Med. 2022 Jan 27;386(4):316-326. (PMID: 35081280)
Clin Rev Allergy Immunol. 2021 Dec;61(3):403-423. (PMID: 34403083)
Ther Adv Chronic Dis. 2023 Aug 4;14:20406223231191049. (PMID: 37546700)
J Am Acad Dermatol. 2021 Sep;85(3):735-736. (PMID: 31325553)
J Dermatolog Treat. 2022 Dec;33(8):3143-3149. (PMID: 36214579)
J Eur Acad Dermatol Venereol. 2019 Aug;33(8):1602-1609. (PMID: 30887594)
J Am Acad Dermatol. 2018 Sep;79(3):556-558.e1. (PMID: 29425723)
Autoimmun Rev. 2023 Jul;22(7):103339. (PMID: 37087083)
Sci Rep. 2021 Oct 26;11(1):21034. (PMID: 34702837)
J Dermatol. 2012 Dec;39(12):1063-4. (PMID: 22594793)
Int J Trichology. 2010 Jan;2(1):63-5. (PMID: 21188031)
JAMA Dermatol. 2018 Nov 1;154(11):1358-1360. (PMID: 30304403)
J Am Acad Dermatol. 2021 Jun;84(6):1691-1694. (PMID: 33484763)
JCI Insight. 2016 Sep 22;1(15):e89776. (PMID: 27699252)
Lancet. 2019 Nov 2;394(10209):1638-1650. (PMID: 31543428)
Am J Clin Dermatol. 2020 Aug;21(4):567-577. (PMID: 32557382)
JAAD Case Rep. 2020 Oct 15;6(12):1286-1287. (PMID: 33294565)
Lancet. 2022 Sep 17;400(10356):908-919. (PMID: 36116481)
Pediatr Dermatol. 2017 Sep;34(5):e271-e272. (PMID: 28884897)
J Am Acad Dermatol. 2020 Mar;82(3):675-682. (PMID: 31437543)
J Am Acad Dermatol. 2020 Apr;82(4):1018-1021. (PMID: 31843657)
Allergy. 2023 Apr;78(4):1047-1059. (PMID: 36271804)
Lancet. 2019 Jan 26;393(10169):318-319. (PMID: 30696569)
J Am Acad Dermatol. 2017 Jan;76(1):22-28. (PMID: 27816293)
Clin Cosmet Investig Dermatol. 2015 Jul 24;8:397-403. (PMID: 26244028)
J Eur Acad Dermatol Venereol. 2022 Nov;36(11):2140-2152. (PMID: 35695074)
Skin Appendage Disord. 2021 Nov;7(6):454-459. (PMID: 34901176)
Dermatology. 2013;227(1):37-44. (PMID: 24008264)
J Am Acad Dermatol. 2009 Oct;61(4):581-91. (PMID: 19608295)
N Engl J Med. 2022 Dec 22;387(25):2317-2330. (PMID: 36546624)
J Allergy Clin Immunol. 2018 Nov;142(5):1631-1634.e13. (PMID: 29981808)
Arch Dermatol Res. 2015 May;307(4):319-31. (PMID: 25638328)
N Engl J Med. 2021 Dec 9;385(24):2230-2240. (PMID: 34879449)
Pediatr Dermatol. 2018 Mar;35(2):164-169. (PMID: 29334143)
J Eur Acad Dermatol Venereol. 2020 Dec;34(12):2898-2901. (PMID: 32531131)
Lancet. 2023 May 6;401(10387):1518-1529. (PMID: 37062298)
Allergy. 2022 Mar;77(3):897-906. (PMID: 34460948)
J Dermatol Sci. 2010 May;58(2):154-7. (PMID: 20388588)
J Am Acad Dermatol. 2023 Sep;89(3):600-602. (PMID: 37207955)
Front Immunol. 2020 Aug 06;11:1768. (PMID: 32849633)
Australas J Dermatol. 2013 Aug;54(3):184-91. (PMID: 23808570)
J Allergy Clin Immunol. 2015 Nov;136(5):1277-87. (PMID: 26316095)
Pediatr Dermatol. 2002 Jul-Aug;19(4):298-301. (PMID: 12220271)
Br J Dermatol. 2004 Jul;151(1):16-23. (PMID: 15270868)
Br J Dermatol. 2020 Oct;183(4):702-709. (PMID: 31970750)
J Invest Dermatol. 2012 Sep;132(9):2192-7. (PMID: 22534877)
Allergy. 2018 Mar;73(3):713-723. (PMID: 29083474)
Allergy. 2021 Oct;76(10):3053-3065. (PMID: 33721346)
فهرسة مساهمة: Keywords: Adverse events; Alopecia areata; Atopy; Dupilumab; Pediatric; Real-world data
المشرفين على المادة: 420K487FSG (dupilumab)
0 (Antibodies, Monoclonal, Humanized)
37341-29-0 (Immunoglobulin E)
تواريخ الأحداث: Date Created: 20240723 Date Completed: 20240723 Latest Revision: 20240726
رمز التحديث: 20240726
مُعرف محوري في PubMed: PMC11266226
DOI: 10.1007/s00403-024-03225-4
PMID: 39042295
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-069X
DOI:10.1007/s00403-024-03225-4